Some specificities in the management of hyperglycemia in patients with diabetic kidney disease

National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012; 60(5): 850−86.

International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2013.

Centers for Disease Control and Prevention (CDC). Incidence of end -stage renal disease attributed to diabetes among persons with diagnosed diabetes-United States and Puerto Rico, 1997-2007. MMWR Morb Mortal Wkly Rep 2010; 59(42): 1361−6.

National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49(Suppl 2): S1−S180.

Molitch ME, Defronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79−S83.

Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care 2004; 28(1): 164−76.

Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007; 27(2): 195−207.

Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuira and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289(24): 3272−7.

American Diabetes Association. Standards of Medical Care in Di-abetes - 2015. Diabetes Care 2015; 38(Suppl 1): S1−S93.

Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33(7): 1536−43.

The Diabetes Control and Complication Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med 1993; 329(14): 977−86.

de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365(25): 2366−76.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854−65.

Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl 2): B21−9.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on mi-crovascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376(9739): 419−30.

Patel A, Mcmahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560−72.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veter-ans with type 2 diabetes. N Engl J Med 2009; 360(2): 129−39.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 di-abetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European As-sociation for the Study of Diabetes (EASD). Diabetes Care 2012; 35(6): 1364−79.

Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M, et al. American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocr Pract 2013; 19(Suppl 2): 1−48.

Drechsler C, Krane V, Ritz E, März W, Wanner C. Glycemic con-trol and cardiovascular events in diabetic hemodialysis pa-tients. Circulation 2009; 120(24): 2421−8.

Freedman BI, Andries L, Shihabi ZK, Rocco MV, Byers JR, Cardona CY, et al. Glycated albumin and risk of death and hospitaliza-tions in diabetic dialysis patients. Clin J Am Soc Nephrol 2011; 6(7): 1635−43.

Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M. Gly-cemic Control and the Risk of Death in 1,484 Patients Receiv-ing Maintenance Hemodialysis. Am J Kidney Dis 2010; 55(5): 875−84.

Saloranta C, Groop L, Ylinen K, Teramo K, Tolppanen EM, Tallgren LG. The usefulness of micro- and macrochromatographic de-terminations of glycohemoglobin in diabetic patients with nephropathy. Clin Nephrol 1986; 25(4): 186−92.

Vos FE, Schollum JB, Walker RJ. Glycated albumin is the pre-ferred marker for assessing glycaemic control in advanced chronic kidney disease. Clin Kidney J 2011; 4(6): 368−75.

Chen H, Wu T, Lin H, Jap T, Hsiao L, Lee S, et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in di-abetic patients with CKD stages 3 and 4. Am J Kidney Dis 2010; 55(5): 867−74.

Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18(3): 896−903.

Fukuoka K, Nakao K, Morimoto H, Nakao A, Takatori Y, Arimoto K, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology 2008; 13(4): 278−83.

Triplitt CL. Understanding the kidneys' role in blood glucose regulation. Am J Manag Care 2012; 18(Suppl 1): S11−6.

Mitrakou A. Kidney: its impact on glucose homeostasis and hormonal regulation. Diabetes Res Clin Pract 2011; 93(Suppl 1): S66-72.

Mather A, Pollock C. Glucose handling by the kidney. Kidney Int 2011; 79(Suppl 120): S1−6.

Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and Pharmacoki-netic properties of insulin in type 1 diabetic patients. Diabetes Care 2001; 24(5): 886−90.

Hasslacher C, Vogt C, Raupp D, Dreyhaupt J. Insulinbedarf bei Typ-1-Diabetikern mit nachlassender Nierenfunktion: Human-Insulin versus Analog-Insulin. Dtsch Med Wochenscher 2007; 132(47): 2500−4.

Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin. Ther Adv Endocrinol Metab 2013; 4(4): 113−21.

Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 4th ed. Philadelphia: American College of Physicians; 1999.

Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insu-lin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005; 60(5): 469−76.

Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Ob-es Metab 2008; 10(10): 811−23.

Campbell I. Oral antidiabetic drugs: their properties and rec-ommended use. Prescriber 2007; 18(6): 56−74.

Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011; 12(1): 57−69.

Nogueira C, Souto SB, Vinha E, Braga DC, Carvalho D. Oral glu-cose lowering drugs in type 2 diabetic patients with chronic kidney disease. Hormones 2013; 12(4): 483−94.

Nye HJ, Herrington WG. Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease. Nephron Clin Pract 2011; 118(4): 380−3.

Home P, Mant J, Diaz J, Turner C. Management of type 2 di-abetes: summary of updated NICE guidance. BMJ 2008; 336(7656): 1306−8.

Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000; 4(Suppl 26): 73−85.

Palmer KJ, Brogden RN. Gliclazide. An update of its pharmaco-logical properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993; 46(1): 92−125.

Cavanaugh KL. Diabetes Management Issues for Patients With Chronic Kidney Disease. Clin Diabetes 2007; 25(3): 90−7.

Budde K, Neumayer H, Fritsche L, Sulowicz W, Stompôr T, Eckland D. The pharmacokinetics of pioglitazone in patients with im-paired renal function. Br J Clin Pharmacol 2003; 55(4): 368−74.

Abe M, Kikuchi F, Kaizu K, Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safe-ly and rapidly in Japanese type 2-diabetic patients on hemodia-lysis. Clin Nephrol 2007; 68(5): 287−94.

Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal impairment on the pharmacokinetics of ex-enatide. Br J Clin Pharmacol 2007; 64(3): 317−27.

Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic signific-ance through sodium glucose co-transporter 2 inhibitors. Me-tab Clin Exp 2014; 63(10): 1228−37.

Stanton RC. Sodium Glucose Transport 2 (SGLT2) Inhibition Decreases Glomerular Hyperfiltration: Is There a Role for SGLT2 Inhibitors in Diabetic Kidney Disease. Circulation 2013; 129(5): 542−4.

Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159(4): 262−74.